Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes

Diabetic Medicine

Volumn 29, Issue 12, 2012, Pages 1515-1523

  Derosa, G ^a   Franzetti, I G ^b   Querci, F ^c   Carbone, A ^d   Ciccarelli, L ^e   Piccinni, M N ^f   Fogari, E ^a   Maffioli, P ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

^c Ospedale Pesenti Fenaroli   (Italy)

^d Hospital Centre of Diabetes   (Italy)

^e RSA Villa Mafalda   (Italy)

^f Fondazione Ospedale Della Caritá   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C PEPTIDE; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EXENDIN 4; FIBRIC ACID DERIVATIVE; GLUCAGON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; OMEGA 3 FATTY ACID; PROINSULIN; TICLOPIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY WEIGHT; CELL FUNCTION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADIPONECTIN; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FASTING; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; ITALY; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VENOMS; WEIGHT LOSS;

EID: 84869111529     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03699.x     Document Type: Article

References (34)

1. Turner RC, Cull CA, Frighi V, Holman RR. Glycaemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
2. Tourrel C, Bailbé D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001; 50: 1562-1570.
3. Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003; 144: 1444-1455.
4. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000; 141: 4600-4605.
5. Triplitt CL. New technologies and therapies in the management of diabetes. Am J Manag Care 2007; 13: 547-554.
6. Byetta. EPAR Summary for the Public. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000698/WC500051840.pdf Last accessed August 2010.
7. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther 2010; 12: 233-240.
8. Derosa G, Putignano P, Bossi AC, Bonaventura A, Querci F, Franzetti IG et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol 2011; 666: 251-256.
9. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010; 59: 887-895.
10. Derosa G, Maffioli P, Ferrari I, Mereu R, Ragonesi PD, Querci F et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res 2010; 42: 663-669.
11. Derosa G, Ragonesi PD, Carbone A, Fogari E, Bianchi L, Bonaventura A et al. Vildagliptin added to metformin on β-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. Diabetes Technol Ther 2012; 14: 475-484.
12. Derosa G, Maffioli P. Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2011; 4: 263-271.
13. Derosa G, Maffioli P. DPP-4 inhibitors: three years of experience. Diabetes Technol Ther 2012; 14: 350-364.
14. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycaemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
15. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycaemic control over 30weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
16. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS et al. Effects of exenatide (exendin-4) on glycaemic control over 30weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
17. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-569.
18. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D. Diminished beta-cell secretory capacity in patients with non insulin dependent diabetes mellitus. J Clin Invest 1984; 74: 1318-1328.
19. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
20. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA et al. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler Thromb Vasc Biol 2006; 26: 2186-2191.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
22. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
23. Holst JJ. Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin. Biochem J 1982; 207: 381-388.
24. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223.
25. Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009; 32: 762-768.
26. Fasching P, Ratheiser K, Nowotny P, Uurzemann S, Parker S, Waldhaus W. Insulin production following intravenous glucose, arginine, and valine: different pattern in patients with impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Metabolism 1994; 43: 385-389.
27. Winer BJ. Statistical Principles in Experimental Design, 2nd edn. New York: McGraw-Hill.
28. Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover non-inferiority trial. Clin Ther 2007; 29: 2333-2348.
29. Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes Metab 2011; 13: 982-989.
30. Pfützner A, Pfützner AH, Larbig M, Forst T. Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diabetes Technol Ther 2004; 6: 405-412.
31. Jackson MB, Ahima RS. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clin Sci 2006; 110: 143-152.
32. Zwacka TP, Hornbach V, Torzewski J. C-reactive protein-mediated lipoprotein uptake by macrophages. Circulation 2001; 103: 1194-1197.
33. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
34. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-614.